Soleno Therapeutics Inc SLNO 深 滬
等待開盤 09-08 09:30:00 美东时间
53.01
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 53.01
- 總市值 276.29万
- 52周最高 90.3199
- 市盈率 靜 135.61
- 換手率 0.00%
- 52周最低 29.43
- 委 比 0.00%
- 總股本 5.21万
- 歷史最高 90.3199
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.81
- 每 手 1
- 風險率 10.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer effective August 17, 2026. Dr. Joshi brings over two decades of leadership experience in drug development, regulatory processes, and lifecycle management. His expertise will support Rhythm’s advancements in next-generation MC4R agonists and its leadership in rare neuroendocrine diseases. Previously, Dr. Joshi served as Chief Development Officer a...
08-17 12:00
Neurocrine slips as safety issues linked to Vykat XR resurface
Shares of Neurocrine Biosciences (NBIX) slipped in the premarket on Wednesday after safety concerns linked to Vykat XR, a rare disease therapy the company added with its acquisition of Soleno Therapeu...
08-12 19:29
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics announced several key leadership appointments to strengthen its executive team. Kevin Norrett was appointed Chief Business Officer, Charles Carter promoted to Chief Financial Officer, Eliseo Salinas joined as Executive R&D Advisor, and Victoria Fort became Chief Strategy Officer. These changes aim to support the company's growth and strategic initiatives in developing innovative treatments for brain disorders.
07-08 11:00
Cantor Fitzgerald Suspends Neutral Rating on Soleno Therapeutics
Cantor Fitzgerald suspends Neutral rating on Soleno Therapeutics (NASDAQ:SLNO).
05-19 20:58
Soleno Therapeutics Completes Merger and Delists from Nasdaq
The latest update is out from Soleno Therapeutics ( ($SLNO) ). On May 18, 2026,...
05-18 21:58
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong earl...
05-18 20:46
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
05-09 05:57
财报速睇 | Soleno Therapeutics 2026财年Q1营收0.95亿美元，同比增长100.0%；归母净利润0.31亿美元，扭亏为盈
华盛资讯5月8日讯，Soleno Therapeutics公布2026财年Q1业绩，公司Q1营收0.95亿美元，同比增长100.0%，归母净利润0.31亿美元，扭亏为盈。
05-08 08:02
